Jade Biosciences, Inc. (JBIO)
NASDAQ: JBIO · Real-Time Price · USD
8.48
+0.42 (5.21%)
At close: Sep 26, 2025, 4:00 PM EDT
8.32
-0.16 (-1.89%)
After-hours: Sep 26, 2025, 4:28 PM EDT
Company Description
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
It also develops JADE201 and JADE-003, which are in preclinical development stage. The company has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. was founded in 2024 and is headquartered in Waltham, Massachusetts.
Jade Biosciences, Inc.
| Country | United States |
| Founded | 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Tom Frohlich |
Contact Details
Address: Building 23, Suite 105 Waltham, Massachusetts 02453 United States | |
| Phone | 781 312 3013 |
| Website | jadebiosciences.com |
Stock Details
| Ticker Symbol | JBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000947559 |
| CUSIP Number | 008064206 |
| ISIN Number | US0080642061 |
| Employer ID | 64-0862173 |
| SIC Code | 6021 |
Key Executives
| Name | Position |
|---|---|
| Tom Frohlich | Chief Executive Officer and Director |
| Bradford D. Dahms Ph.D. | Chief Financial Officer |
| Dr. Andrew James King D.V.M., Ph.D. | Chief Scientific Officer and Head of Research & Development |
| Elizabeth Balta | General Counsel and Corporate Secretary |
| Lori Stewart | Senior Vice President of People |
| Dr. Jason Wright Ph.D. | Senior Vice President, Chemistry, Manufacturing and Controls |
| Jonathan Quick | Senior Vice President of Finance |
| Valerie Fauvelle | Senior Vice President of Regulatory and Quality |
| Amy Sullivan | Senior Vice President of Development Operations |
| Sandy Lewis | Senior Vice President, Biometrics and Clinical Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2025 | SCHEDULE 13G/A | Filing |
| Apr 28, 2025 | SCHEDULE 13G/A | Filing |
| Apr 17, 2025 | 15-12G | Securities registration termination |
| Apr 17, 2025 | 15-12G | Securities registration termination |
| Apr 9, 2025 | EFFECT | Notice of Effectiveness |
| Apr 9, 2025 | EFFECT | Notice of Effectiveness |
| Apr 8, 2025 | POS AM | Post-Effective amendments for registration statement |
| Apr 8, 2025 | POS AM | Post-Effective amendments for registration statement |
| Apr 7, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 7, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |